TITLE

Low-molecular-weight heparins as adjunctive therapy to thrombolytics: extracting the best data

AUTHOR(S)
Bailey, Alison L.; Steinhubl, Steven R.
PUB. DATE
May 2006
SOURCE
CMAJ: Canadian Medical Association Journal;5/9/2006, Vol. 174 Issue 10, p1431
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
Discusses a study that evaluated the safety and efficacy of the thrombolytic drug tenecteplase plus either enoxaparin or unfractionated heparin in cases of ST-segment elevation myocardial infarction by doing a pooled analysis of data from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 and ASSENT-3 PLUS trials. Purpose of the ASSENT-3 trial; Reduction in rates of reinfarction and recurrent ischemia; Risk of intracranial hemorrhage among patients older than 75 years who received enoxaparin and tenecteplase.
ACCESSION #
21062640

 

Related Articles

  • Antithrombotic and interventional treatment options in cardioembolic transient ischaemic attack and ischaemic stroke. McCabe, D. J. H.; Rakhit, R. D. // Journal of Neurology, Neurosurgery & Psychiatry;Jan2007, Vol. 78 Issue 1, p14 

    Peer-reviewed data pertaining to anti-thrombotic and interventional therapy for transient ischaemic attack (TIA) or ischaemic stroke patients with non-valvular atrial fibrillation, atrial flutter, interatrial septal abnormalities, or left ventricular thrombus were reviewed. Long-term oral...

  • alteplase.  // Royal Society of Medicine: Medicines;2002, p48 

    This article provides information on the drug alteplase. The drug is used therapeutically as a fibrinolytic, because it has the property of breaking up blood clots. It is used in serious conditions such as myocardial infarction and pulmonary embolism. Administration is by injection.

  • Metalyse.  // Royal Society of Medicine: Medicines;2002, p356 

    The article presents information on metalyse, a proprietary, prescription-only preparation of the fibrinolytic tenecteplase. This drug can be used to treat myocardial infarction. It is available in a form for injection.

  • Rapilysin.  // Royal Society of Medicine: Medicines;2002, p469 

    This article presents information on Rapilysin, a proprietary, prescription-only preparation of the fibrinolytic drug reteplase. It can be used to treat myocardial infarction, and is available in a form for injection.

  • Heart drugs can be a bust. Schultz, Stacey // U.S. News & World Report;05/29/2000, Vol. 128 Issue 21, p67 

    Reports on two studies which show that the clot-busting drugs often given to people who suffer a heart attack can be harmful. Drugs, called thrombolytics, which can benefit younger heart attack victims, but may harm victims over 76-years-old; Angioplasty as a safer option for older heart attack...

  • Treatment Options for STEMI Patients who Present to Hospitals without PCI Capability. Bates, Eric R. // Current Medical Literature: Cardiology;2009, Vol. 28 Issue 3, p53 

    The article discusses treatment options for patients with ST-segment elevation myocardial infarction (STEMI) who present to hospitals without primary percutaneous coronary intervention (PPCI). A comparison of approved fibrinolytic agents, such as streptokinase and reteplase, is presented, as...

  • ASPIRIN AFTER THROMBOLYSIS FOR MI. Seaton, Terry L. // Journal of Family Practice;Mar1997, Vol. 44 Issue 3, p249 

    The article examines the optimal method of preventing reinfarction and death in patients who receive a thrombolytic for the treatment of acute myocardial infarction. The study enrolled patients who were treated with anistreplase. Risks of reinfarction, cardiac death, cardiac events and bleeding...

  • Facilitated Percutaneous Coronary Intervention: Pharmacological and Mechanical Synergy in Reperfusion for ST-Elevation Myocardial Infarction. Part 2. Choo, Joseph; Young, John; Kereiakes, Dean // Current Medical Literature: Interventional Cardiology Monitor;2004, Vol. 11 Issue 2, p29 

    Discusses the use of fibrinolytic drugs with percutaneous coronary intervention (PCI). Steps in minimizing bleeding complications with improved vascular access care and anticoagulation monitoring; Benefit attributable to abciximab in conjunction with PCI for STEMI.

  • A Comparison of Continuous Infusion of Alteplase with Double-Bolus Administration for Acute Myocardial Infarction.  // New England Journal of Medicine;10/16/97, Vol. 337 Issue 16, p1124 

    Background: Accelerated infusion of alteplase (tissue plasminogen activator) over a period of 90 minutes induces more rapid lysis of coronary-artery thrombi than a 3-hour infusion. With two bolus doses of alteplase, further shortening the duration of administration, complete reperfusion was...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics